Elucidating causative gene variants in hereditary Parkinson's disease in the Global Parkinson's Genetics Program (GP2)

Lange LM 1 , Avenali M 2 , Ellis M 3 , Illarionova A 4 , Keller Sarmiento IJ 5 , Tan AH 6 Show all authors , Madoev H 1 , Galandra C 2 , Junker J 1 , Roopnarain K 1 , Solle J 7 , Wegel C 8 , Fang ZH 4 , Heutink P 4 , Kumar KR 9 , Lim SY 6 , Valente EM 2 , Nalls M 10 , Blauwendraat C 11 , Singleton A 11 , Mencacci N 5 , Lohmann K 1 , Klein C 12 , Global Parkinson’s Genetic Program (GP2)

Affiliations 

  • 1 Institute of Neurogenetics, University of Lübeck, Lübeck, Germany
  • 2 IRCCS Mondino Foundation, Pavia, Italy
  • 3 Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord, NSW, Australia
  • 4 German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
  • 5 Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
  • 6 Division of Neurology, Department of Medicine, and the Mah Pooi Soo and Tan Chin Nam Centre for Parkinson's and Related Disorders, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 7 Department of Clinical Research, Michael J. Fox Foundation for Parkinson's Research, New York City, NY, USA
  • 8 Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA
  • 9 Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
  • 10 Data Tecnica International, Washington, DC, USA
  • 11 Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
  • 12 Institute of Neurogenetics, University of Lübeck, Lübeck, Germany. christine.klein@neuro.uni-luebeck.de
NPJ Parkinsons Dis, 2023 Jun 27;9(1):100.
PMID: 37369645 DOI: 10.1038/s41531-023-00526-9

Abstract

The Monogenic Network of the Global Parkinson's Genetics Program (GP2) aims to create an efficient infrastructure to accelerate the identification of novel genetic causes of Parkinson's disease (PD) and to improve our understanding of already identified genetic causes, such as reduced penetrance and variable clinical expressivity of known disease-causing variants. We aim to perform short- and long-read whole-genome sequencing for up to 10,000 patients with parkinsonism. Important features of this project are global involvement and focusing on historically underrepresented populations.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications